Chimerism New Products

Extension of marker set Addition of 10 markers

Extension of marker set With corresponding new IFU Information included on added markers Figure on marker locations Additional information on: Fluorophores and channels for KMRtype multiplex Data analysis with qPCR and KMRengine

Pre-transplant sample Needed for monitoring Limited over time Replacement with previous post-transplant sample Experiments with reagents have been performed Software needs to be adjusted  future development

HLA markers Early access program

Delicate HLA balance Matched HLA Mismatched HLA To prevent Graft-versus-Host disease Mismatched HLA For Graft-versus-Leukemia effect Residual disease Control residual disease. Important to know more about HLA expression at time of relapse. Removal of T cells in favour of one and not in favour of the other.

Delicate HLA balance Cancer cells evade immune system Down regulation of HLA No mismatched HLA for current donor HLA status at time of relapse for treatment Control residual disease. Important to know more about HLA expression at time of relapse. Removal of T cells in favour of one and not in favour of the other.

Current marker set Bi-allelic variants Well described and published Insertions/deletions SNPs Well described and published No HLA markers yet. Tricky area.

Collaboration We do not work alone. We work with the experts in the field. Collaboration with Essen and Milano.

HLA locus selection Haploidentical family donors Recipient Donor B C DR DQ DP Matched unrelated donors (10/10) Recipient Donor A B C DR DQ DP Which loci are taken into account during development.

Practical example Example that HLA markers work in practise

In conclusion Monitoring HLA loss at time of relapse is important for treatment strategy HLA markers in addition to KMR markers A product in development Collaboration with Essen and Milano.

Other updates Further extension and integration of markers CE-IVD registration Your ideas?